Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab® Systems
News Jul 09, 2009
Gyros AB announces that it has raised SEK 80 million (approximately €7.5m) in an equity fund raising led by SLS Invest, the Company’s leading shareholder.
The new funds will enable Gyros to drive the further commercialization of its Gyrolab technology. This technology platform is gaining traction with leading pharma and biotech companies as well as CROs and CMOs focused on the accelerated development of new biopharmaceuticals.
A growing list of more than 20 companies worldwide, including Merck, Medimmune, GSK, Amgen, Pfizer, Ablynx and ThromboGenics, currently benefit from Gyros’ unique Gyrolab systems, with an installed base of 40 systems.
SLS Invest is a Scandinavian life science investor and its decision to lead this funding round reflects confidence in the potential of Gyros’ automated micro-immunoassays for accelerating the development of therapeutic proteins. It also is in line with SLS Invest’s revised investment approach, which is centered on providing greater support to a smaller number of its portfolio companies.
SLS Invest’s confidence in Gyros’s future success is evidenced by the fact that, following the financing, it owns an 88% shareholding in Gyros.
Lipid droplets have been found to play critical roles in the life cycles of certain proteins involved in gene expression. Now, a new study describes how lipid droplets regulate these proteins. The research has implications for understanding what helps embryos survive and could cause us to reconsider how we look at lipid-related diseases like obesity.READ MORE